Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients
|
|
- Edward Cunningham
- 5 years ago
- Views:
Transcription
1 Evaluating the Total Costs of Chemotherapy-Induced Toxicity: Results from a Pilot Study with Ovarian Cancer Patients ELIZABETH A. CALHOUN, CHIH-HUNG CHANG, EMILY E. WELSHMAN, DAVID A. FISHMAN, JOHN R. LURAIN, CHARLES L. BENNETT The Institute for Health Services Research and Policy Studies, Department of Obstetrics and Gynecology, the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Department of Medicine, Division of Hematology/Oncology, Chicago, Illinois, USA and the Chicago VA Healthcare System/Lakeside Division, Chicago, Illinois, USA ABSTRACT Purpose. While chemotherapy-related toxicities affect cancer patients activities of daily living and result in large expenditures of medical care for treatment, few studies have assessed the out-of-pocket and indirect costs incurred by patients who experience toxicity. The objective of this study was to evaluate the feasibility of obtaining detailed and comprehensive cost information from patients who experienced neutropenia, thrombocytopenia, or neurotoxicity during treatment. Methods. Ovarian cancer patients who experienced chemotherapy-associated hematologic or neurologic toxicities were asked to record detailed information about hospitalization, laboratories, physician visits, phone calls, home visits, medication, medical devices, lost productivity, and caregivers. Resource estimates were converted into cost units, with direct medical cost estimates based on hospital cost-accounting data and indirect costs (i.e., productivity loss) on modified labor force, employment, and earnings data. INTRODUCTION Approaches to cancer treatment have rapidly grown complex and costly causing heightened awareness among patients, physicians, employers and insurance providers. Annual costs for cancer-related treatments are about $107 billion, accounting for 20% of all health care costs [1]. These costs represent the societal value of oncology-related resources consumed in providing cancer care, including the Key Words. Costs Toxicities Chemotherapy Results. Direct medical costs were highest for neutropenia (mean of $7,546/episode), intermediate for thrombocytopenia (mean of $3,268/episode), and lowest for neurotoxicity (mean of $688/episode). Indirect costs relating to patient and caregiver loss and payments for caregiver support were substantial, accounting for $4,220, $3,834, and $4,282 for patients who developed neurotoxicity, neutropenia, and thrombocytopenia, respectively. The total costs of chemotherapy-related neurotoxicity, neutropenia, and thrombocytopenia were $4,908, $11,830, and $7,550. Conclusion. Our study has shown that, with the assistance of patients who are experiencing toxicity, estimation of the total costs of cancer-related toxicities is feasible. Indirect costs, while not included in prior estimates of the costs of toxicity studies, accounted for 34% to 86% of the total costs of cancer supportive care. The Oncologist 2001;6: costs associated with drugs and devices, consultation with physicians, and hospital costs. However, most of the detailed information on cancer costs relates to the direct medical expenditures for cancer treatment, rather than care required for treatment-related toxicity. Very little is known about the societal value of resources used as a result of toxicity, including both the direct medical costs for supportive care and indirect costs of care. The indirect costs include Correspondence: Elizabeth A. Calhoun, Ph.D., The Institute for Health Services Research and Policy Studies, Department of Obstetrics and Gynecology, the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 339 E. Chicago Avenue, Room 717, Chicago, Illinois 60611, USA. Telephone ; Fax: ; e-calhoun@northwestern.edu. Received June 11, 2001; accepted for publication August 30, AlphaMed Press /2001/$5.00/0 The Oncologist 2001;6:
2 Calhoun, Chang, Welshman et al. 442 the value of lost time from as a result of the illness, decreased productivity while at, time or money spent by people looking after the patient, and premature retirement or death [2-4]. It is possible that the total costs of cancer care have been markedly underestimated. In this study, we evaluated the feasibility of obtaining detailed estimates of the total direct and indirect costs of toxicities for women with a particular type of tumor ovarian cancer. Ovarian cancer is the fourth most common cancer in women. In 2000, it affected over 23,000 women and accounted for 14,000 deaths [5]. Supportive care issues are especially large for ovarian cancer, as 75% of women with this malignancy have advanced disease at presentation. Almost all of these individuals receive several cycles of multi-drug chemotherapy regimens, and the majority experience at least one episode of chemotherapy-associated toxicity [6, 7]. METHODS The objective of this study was to evaluate the feasibility of obtaining detailed information on direct and indirect costs of toxicity among a cohort of women receiving chemotherapy for ovarian cancer. We focused on three common toxicities neurotoxicity, neutropenia, and thrombocytopenia. Patients were queried about resources used as a result of the toxicity, including outpatient visits from traditional and alternative health care providers, labs, phone calls, hospitalizations, home health visits, medications (including over the counter), medical devices, time missed from, and time spent by caregivers to assist with activities of daily living during episodes of toxicity. Resource utilization was tracked from study entry, operationally defined as coincident with the onset of a toxicity and continued through the end of the toxicity episode. The Neurotoxicity Group had to meet at least one of the following: signs and symptoms of grade 2 or higher peripheral neuropathy (e.g., burning/tingling in fingers/toes, difficulty buttoning buttons); loss of feeling, numbness; signs of ototoxicity (hearing loss); and blurred vision. The Hematotoxicity Group had to meet at least one of the following: grade 3 or 4 neutropenia (neutrophil count less than 1,000/mm 3 ) in the past 2 weeks, and thrombocytopenia (Eastern Cooperative Oncology Group score for platelets less than 100,000). Prior to study initiation, the project was approved by the Cancer Research Organization of the Robert H. Lurie Comprehensive Cancer Center and the Human Subjects Protection Committee of Northwestern University. In clinic, trained research assistants obtained informed consent, reviewed the instrument instructions with each participant, and answered questions as needed. Episodes consisted of up to 9 months for the Neurotoxicity Group and up to 3 months for the hematologic toxicity groups, generally representing the time period for which gynecologic oncologist consultants felt that these toxicities might be expected to have an impact on one s life. Economic variables were collected at baseline and every 3 months during the follow-up period. All patients were recruited within 1 month of experiencing the toxicity and, by design, no patient met criteria in more than one of the toxicity groups. Most questionnaires were obtained in-person at clinic visits. Patients who were unable to complete the instruments at the time of their visit were given a postage-paid return envelope. All patients whose mailed questionnaires had not been received by Northwestern within 7 days were interviewed over the phone. Only a small number of patients were not interviewed in clinic. The economic data collected for this study included a detailed listing of the medical care services received by subjects, attribution of the cause of each service, and loss of time because of toxicities. Primary analyses included only those resources that were directly attributed to a toxicity or its treatment. Each toxicity was analyzed separately. The second part of the economic analysis assigned a value to each item. The unit costs came from standard sources, such as hospital bills for in-patient stays, the Medicare Physician Fee Schedule for outpatient services, and The Red Book for pharmaceuticals [8]. The device costs were calculated based on the average price from three national drugstores. Phone calls to medical providers were estimated to be 15 minutes to a physician or a nurse, depending upon with whom the patient spoke. Standard unit costs were multiplied by the average number of visits, labs, hospitalizations, medications, and medical devices to calculate an estimate of the average cost per person in each of the three study groups. Indirect costs (i.e., productivity loss) were based on modified labor force, employment, and earnings data [9]. Finally, a total cost of toxicity was derived for each participant. RESULTS The study included economic information on chemotherapy-related neurotoxicity (n = 42 patients), neutropenia (n = 26 patients), and thrombocytopenia (n = 15 patients). Direct medical costs were highest for neutropenia (mean of $7,546 per episode), intermediate for thrombocytopenia (mean of $3,268 per episode), and lowest for neurotoxicity (mean of $688 per episode) (Table 1). For the hematologic toxicities, inpatient medical care accounted for the largest part of the direct medical costs ($6,204 for neutropenia [82% of the total direct costs] and $2,654 for thrombocytopenia [81% of the total costs]), followed by outpatient pharmaceuticals ($721 for neutropenia; 10% of the costs). In contrast, neurotoxicity, while disabling, was
3 443 Chemotherapy-Induced Toxicity Costs Table 1. Direct costs of chemotherapy-associated toxicity for women with ovarian cancer costs (n = 42) Direct costs costs (n = 26) Direct costs costs (n = 15) Direct costs Direct costs $688 $7,546 $3,268 Hospital inpatient $0 0% $6,204 82% $2,657 81% Physician visits $211 31% $250 3% $250 8% ER visits $0 0% $77 1% $50 1.5% Drugs/devices $432 63% $721 10% $23 <1% Home health $0 0% $0 0% $0 0% Labs $0 0% $252 3% $271 8% Phone calls to medical/ nursing providers $45 6.5% $41.5% $17 <1% Table 2. Indirect costs of chemotherapy-associated toxicity for women with ovarian cancer costs (n = 42) Indirect costs costs (n = 26) Indirect costs costs (n = 15) Indirect costs Indirect total $4,220 $3,834 $4,282 Patient loss $620 15% $2,422 63% $2,122 50% Caregiver loss $2,837 67% $711 19% $280 6% Paid caregiver $496 18% $702 18% $1,880 44% Table 3. Total costs of chemotherapy-associated toxicity for women with ovarian cancer costs (n = 42) Total costs costs (n = 26) Total costs costs (n = 15) Total costs Total costs $206,138 $295,878 $113,257 Direct total $28,878 14% $196,189 66% $49,024 43% Indirect total $177,260 86% $99,689 34% $64,233 57% Mean total per patient $4,908 $11,380 $7,550 not associated with any inpatient care and accounted for $432 in outpatient pharmaceuticals and devices (63% of the total direct costs). Indirect costs relating to patient and caregiver loss and payments for caregiver support were substantial, accounting for $4,220, $3,834, and $4,282 for ovarian cancer patients who developed neurotoxicity, neutropenia, and thrombocytopenia, respectively (Table 2). Indirect costs for hematologic toxicity were primarily associated with patient loss ($2,422 for neutropenia [63% of the total indirect costs] and $2,122 for thrombocytopenia [50% of the total costs]), while neurotoxicity was associated with $2,837 in caregiver loss (67% of the total costs). In total, the costs of chemotherapyrelated neurotoxicity, neutropenia, and thrombocytopenia were $4,908, $11,830, and $7,550, with indirect costs accounting for 86%, 34%, and 57% of the total costs of toxicity, respectively (Table 3). Figure 1 depicts the status of patients at time of study entry and at follow-up. DISCUSSION In this pilot study, we found that it was feasible to obtain detailed resource utilization information from a cohort of ovarian cancer patients during a time when chemotherapy-associated neurologic or hematologic toxicity occurred. For these 83 women, an estimated $630,000 in total costs were estimated to have been incurred as a result of chemotherapy-related toxicity, with over half of these costs being attributed to lost wages for the patient or caregiver, or direct payments to a caregiver. Our estimates of the direct costs of chemotherapy-associated toxicities can be compared to those included in prior costs of toxicity studies [6, 10-14]. These studies have focused on neutropenia, as a result of widespread adoption of the hematologic colony-stimulating factors, G-CSF and
4 Calhoun, Chang, Welshman et al Patients Neurotoxicity (n = 42) Neutropenia (n = 26) Thrombocytopenia (n = 15) 7 w/ 20 w/o 15 ing 9 w/ 15 w/o 2 ing 7 w/ 8 w/o 0 ing Figure 1. Depicts the status of patients at time of study entry and at follow-up. GM-CSF. Detailed cost analyses reports indicate a mean per episode for direct costs ranging from $2,605 when care is delivered primarily as an outpatient to $21,417, when care is delivered exclusively as an inpatient [10-14]. Our direct cost estimate for neutropenia, $7,546 per episode, was associated with care that was administered as an outpatient for about half of the individuals with this toxicity. One prior study of thrombocytopenia estimated mean direct costs of $1,818 per episode, primarily for inpatient treatment with platelet transfusions [15]. In contrast, our cost estimate of direct costs for this toxicity was $3,268. It is likely that the assessment of post-hospitalization medical resource use in our study, but not in the earlier report, accounts for some of the difference in thrombocytopenia cost estimates. There have been no studies of the direct medical costs of chemotherapy-associated neurotoxicity. While a few studies have measured indirect costs of care for cancer patients, none have included a detailed breakdown of costs [2-4]. More than 90% of cancer patients use paid caregivers for at least one activity, ranging from financial assistance to medical care to personal care. Estimates from several years ago suggest that indirect costs may be as much as $1,000 per month [3]. In our study, paid caregiver costs accounted for a mean of $496 for neurotoxicity support, $702 for thrombocytopenia support, and $1,880 for neutropenia support. Of note, two-thirds of patients with neurotoxicity discontinued because of toxicity versus only 20% for neutropenia and 0% for thrombocytopenia. Specific examples of neurotoxicity loss include a woman who was no longer able to perform her duties as a bank teller and several women unable to perform job-related computer activities. As cancer treatment is primarily administered on an outpatient basis, informal caregivers assume a large responsibility for patient care at home. One of the greatest worries of cancer patients is lost income, resulting from the use of sick and vacation time or from lost for people who are self-employed. Although cancer treatment often results in fatigue and weakness, a quick return to is crucial for many. One study from the early 1990s reported a three-month average of $1,258 in lost earnings for patients [4]. In contrast, in our study, mean lost wages for patients ranged from $2,100 to $2,400 for hematologic toxicities and $620 for neurotoxicity. Of note, 52% of the ovarian cancer patients in our study were not ing at the time of diagnosis and did not incur any lost wages as a result. There are limitations to this pilot study. First, our data collection methods relied upon patient reporting of many of the outpatient costs of care. This method has been used in other comprehensive cost-of-illness studies of persons with serious medical illnesses and has been validated where possible against medical bills. Second, only women with ovarian cancer were included in this pilot study. This allowed for efficiencies of recruitment and data collection, with one research assistant spending most of her time in the gynecologic oncology clinic setting. Despite being in the middle of treatment with chemotherapy, the patients readily complied with the study interview and follow-up assessments. We are now extending the study methods to include costs of cancer care for persons with lung, prostate, breast, and colon cancer, in order to provide a broader estimate of the total costs of cancer care. Together, these malignancies account for over 60% of all new cancer diagnoses annually. In conclusion, this study has shown that, with the involvement of patients engaged in active treatment programs, evaluation of the total direct and indirect costs of cancer-associated toxicities is feasible. These studies are likely to be important to policymakers as indirect costs, which accounted for 34% to
5 445 Chemotherapy-Induced Toxicity Costs 86% of the total costs of cancer supportive care in this study, have rarely been included in the few prior estimates of the cost of chemotherapy-related toxicities. ACKNOWLEDGMENT Supported in part by unrestricted grants from Amgen Inc. and ALZA Inc. REFERENCES 1 Pfister DG. Importance of economic evaluation in oncology. New economic challenges in oncology practice. World Health CME 1997; Moore K. Breast cancer patients out-of-pocket expenses. Cancer Nurs 1999;22: Houts P, Lipton A, Harvey HR et al. Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 1984;53: Given B, Given C, Stommel M. Family and out-of-pocket costs for women with breast cancer. Cancer Pract 1994;2: American Cancer Society [database online]: Cancer Facts and Figures Atlanta, GA: American Cancer Society, Inc., Bennett, CL, Golub R, Calhoun EA et al. Cost-utility assessment of amifostine as first-line therapy for ovarian cancer. Int J Gynecol Cancer 1998:8: Christian M, Trimble E. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994;55:S143-S Red Book, Medical Economics Company, Inc. Montvale, NJ: 1999: Statistical Abstract of the United States 1999, 119th Edition, U.S. Department of Commerce Economics and Statistics Administration, U.S. Census Bureau. 10 Hutton J, Brown R, Borowitz M et al. A new decision model for cost-utility comparisons of chemotherapy in breast cancer. Pharmacoeconomics 1996:9(suppl 2): Dranitsaris G. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection. Support Cancer Care 1997;5: Souetre E, Quing W. Economic analysis of lenogastrim in the correction of neutropenia following chemotherapy for non-hodgkin s lymphoma. Pharmacoeconomics 1994;6 (suppl 2): Lyman GH, Kuderer NM, Green J. The economics of febrile neutropenia. Blood 1996;88(suppl 1):346a. 14 Lyman GH, Kuderer NM, Balducci L. Thresholds for the use of recombinant human colony stimulating factors based on revised cost estimates incorporating indirect medical, nonmedical, and intangible cost considerations. Blood 1996;88(suppl 1):346a. 15 Malone D, Sullivan S, Black D et al. The cost of treating chemotherapy-induced thrombocytopenia. Proc Am Soc Clin Oncol 1995;14:305a.
Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR814752Original ArticleOutpatient Treatment of Febrile NeutropeniaCosler et al. Volume 8 Number 1 2005 VALUE IN HEALTH Effect of Outpatient
More informationEvaluating the Supportive Care Costs of Severe Radiochemotherapy-Induced Mucositis and Pharyngitis
1446 Evaluating the Supportive Care Costs of Severe Radiochemotherapy-Induced Mucositis and Pharyngitis Results From a Northwestern University Costs of Cancer Program Pilot Study With Head and Neck and
More informationHana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN)
The Costs of Smoking Hana Ross, PhD American Cancer Society and the International Tobacco Evidence Network (ITEN) Why Do We Study the Cost of Smoking? To assess the economic impact of smoking behavior
More informationA COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:
A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation
More informationTobacco Health Cost in Egypt
1.Introduction 1.1 Overview Interest in the health cost of smoking originates from the desire to identify the economic burden inflicted by smoking on a society. This burden consists of medical costs plus
More informationAttitudes and Beliefs of Prostate Cancer Patients Towards Out-of-Pocket Payment
Attitudes and Beliefs of Prostate Cancer Patients Towards Out-of-Pocket Payment By Olivia S. Jung Mentor: Justin E. Bekelman, MD Supported by LDI Pilot Grant August 12, 2011 Increasing costs of cancer
More informationTHE COST DRIVERS OF CANCER CARE
THE COST DRIVERS OF CANCER CARE Debra Patt, MD, MPH, MBA David Eagle, MD Ted Okon, MBA Don Sharpe 20156Community Oncology Alliance 1 Welcome & Introductions Debra Patt, MD, MPH, MBA Director of Public
More informationOncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications
1 ONSQIR 1 Non-PRQS Measure Oncology Nursing Society Registry in Collaboration with CE City 2015 Performance Measure Specifications Performance Measure Name: Symptom Assessment 1-o1a Symptom Assessment
More informationThe Economic Burden of Hypercholesterolaemia
The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia
More informationA Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data
RESEARCH A Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data OBJECTIVE: To describe a model for analyzing the unnecessary costs
More informationHow health plans can improve cancer care: from utilization management to delivery reform
Quality health plans & benefits Healthier living Financial well being Intelligent solutions How health plans can improve cancer care: from utilization management to delivery reform Michael Kolodziej, M.D.,
More information2014 Medicare (and Private Insurance) Payment Reform for Oncology. Ensuring the Delivery of Quality & Value-Based Cancer Care
2014 Medicare (and Private Insurance) Payment Reform for Oncology Ensuring the Delivery of Quality & Value-Based Cancer Care PHASE 1 PHASE 2 PHASE 3 PHASE 4 Quality Reporting Quality & Value Performance
More informationAlzheimer s disease affects patients and their caregivers. experience employment complications,
Alzheimer s Disease and Dementia A growing challenge The majority of the elderly population with Alzheimer s disease and related dementia are in fair to poor physical health, and experience limitations
More informationAn Overview of Health Economics Data and Expertise in Cancer
An Overview of Health Economics Data and Expertise in Cancer Peter Smith, (Professor of Health Policy, Imperial College London) Mauro Laudicella (Research Fellow, Imperial College London) Source: A. Maynard
More informationTHE EARLY TREATMENT FOR HIV ACT: MEDICAID COVERAGE FOR PEOPLE LIVING WITH HIV
THE EARLY TREATMENT FOR HIV ACT: MEDICAID COVERAGE FOR PEOPLE LIVING WITH HIV INTRODUCTION The Early Treatment for HIV Act (ETHA) would allow states to extend Medicaid coverage to uninsured, non-disabled
More informationWhat Does Breast Cancer Treatment Cost and What Is It Worth?
What Does Breast Cancer Treatment Cost and What Is It Worth? Elena B. Elkin, PhD Center for Health Policy and Outcomes Memorial Sloan-Kettering Cancer Center Is This Drug Worth the Cost? Ixabepilone added
More informationDiabetes mellitus is a disorder caused by insufficient or non
The Economic Burden of Diabetes Mellitus in the WHO African Region Introduction Diabetes mellitus is a disorder caused by insufficient or non production of the hormone insulin by the pancreas. There are
More informationThe Socio Economic Impact of radiation treatments on patients and their families
The Socio Economic Impact of radiation treatments on patients and their families Jeanette Hardwick, RTT, MBA Supervising Radiation Therapist Radiation Medicine Department Roswell Park Cancer Institute
More informationCrystal T. Pike, 1 Howard G. Birnbaum, 1 Catherine E. Muehlenbein, 2 Gerhardt M. Pohl, 2 and Ronald B. Natale Introduction
Chemotherapy Research and Practice Volume 2012, Article ID 913848, 10 pages doi:10.1155/2012/913848 Research Article Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral
More informationThe Cost of Alcohol and Drug Abuse in Maine, 2010
The University of Maine DigitalCommons@UMaine Anthropology Faculty Scholarship Anthropology 4-2013 The Cost of Alcohol and Drug Abuse in Maine, 2010 Anne L. Rogers Maine Office of Substance Abuse and Mental
More informationThe New Role of Cancer Patient Engagement in Value Based Models
Mini Summit XIX: Case Studies in Specialty Medical Homes: How to Design APMs to Support Patients with Serious Health Conditions that Cannot be Managed by a PCP Ray Page, DO PhD The New Role of Cancer Patient
More informationManaging Older Patients With Lymphoma and Multiple Myeloma
2006 ONS Congress Webcast Evaluation Form Managing Older Patients With Lymphoma and Multiple Myeloma Session length: 1 hour, 45 minutes Contact hours: 1.5 Pharmacology hours offered: 15 minutes How to
More informationMember-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
More informationSummary. Table 1 Blinatumomab administration, as per European marketing authorisation
Cost-effectiveness of blinatumomab (Blincyto ) for the treatment of relapsed or refractory B precursor Philadelphia chromosome negative acute lymphoblastic leukaemia in adults. The NCPE assessment of blinatumomab
More information$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)
Benefit Summary Outpatient Prescription Drug Illinois 5/50/100/250 Plan 455 Your Co-payment and/or Co-insurance is determined by the tier to which the Prescription Drug List (PDL) Management Committee
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More informationEconomics of cancer from the patient (and family) perspective
Economics of cancer from the patient (and family) perspective Linda Sharp, Paul Hanly, Alan O Ceilleachair, Mairead Skally, Aileen Timmons linda.sharp@ncri.ie NCIN Economics of cancer workshop October
More informationCompetent Pain Management for Older Patients With Cancer
Session length: 2 hours, 53 minutes Contact hours: 3.5 Pharmacology hours offered: 30 minutes 2005 ONS Virtual Institutes of Learning Evaluation Form Competent Pain Management for Older Patients With Cancer
More informationSetting The setting was secondary care. The economic study was conducted in the USA.
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis Elkin E B, Weinstein K C, Winer E P, Kuntz K M, Schnitt S J, Weeks J C Record Status This is a critical
More informationA cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M
A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets
More informationThe ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.
HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million
More information2012 Assessment of St. Lucie County s Social, Health, and Public Safety Services
2012 Assessment of St. Lucie County s Social, Health, and Public Safety Services April 5, 2013 140 Intracoastal Pointe Drive, Suite 212 Jupiter, FL 33477-5064 561.744.5662 Fax: 561.575.7396 www.sra-researchgroup.com
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationDo OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018
Question: Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 An examination of health improvements, utilization & cost of care for
More informationThe Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data
National Center on Birth Defects and Developmental Disabilities The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data Scott
More informationLowering epilepsy-related treatment costs in the era of patient choice and value-based care
Lowering epilepsy-related treatment costs in the era of patient choice and value-based care In-home EEG offers cost-effective, reliable alternative to traditional diagnostic services 01 Introduction One
More informationBETTER WAYS TO PAY FOR CANCER CARE Creating Win-Win-Win Approaches for Oncologists, Cancer Patients, and Payers
BETTER WAYS TO PAY FOR CANCER CARE Creating Win-Win-Win Approaches for Oncologists, Cancer Patients, and Payers Harold D. Miller President and CEO Center for Healthcare Quality and Payment Reform Physicians
More informationEconomic Evaluation. Defining the Scope of a Costeffectiveness
Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes
More informationThis slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both
This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both direct and indirect and the projected burden of diabetes,
More informationGenomic Health, Inc. Oncotype DX Colon Cancer Assay Clinical Compendium March 30, 2012
Economic Validity Eligibility and Addressability for Use of the Assay An important distinction should be made between the total population of patients eligible for the Oncotype DX Colon Cancer assay, and
More informationObesity: Trends, Impact, Complexity
Obesity: Trends, Impact, Complexity Ross A. Hammond, Ph.D. Director, Center on Social Dynamics & Policy Senior Fellow, Economic Studies Program The Brookings Institution Attorneys General Education Program
More informationCancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition
Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost
More informationThe impact of pharmaceutical innovation on New Zealand cancer patients
The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer
More informationUCLA Alzheimer s and Dementia Care Program. 200 UCLA Medical Plaza, Suite 365A Los Angeles, CA
UNIVERSITY OF CALIFORNIA, LOS ANGELES UCLA BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO SANTA BARBARA SANTA CRUZ Alzheimer s and Dementia Care Program 200 UCLA Medical Plaza,
More informationDiabetes Education and Diabetes Prevention Education Needs Assessment, Las Vegas, Nevada
Diabetes Education and Diabetes Prevention Education Needs Assessment, Las Vegas, Nevada Julie Plasencia, MS, RD University of Nevada Cooperative Extension 2009 1 Table of Contents Introduction... 3 Objective...
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer
2006 ONS Congress Webcast Evaluation Form Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer Session length: 1 hour, 49 minutes Contact hours: 1.6 Pharmacology hours offered:
More informationMigraine is a very common medical disorder
MENSTRUALLY RELATED MIGRAINE: IMPLICATIONS FOR EMPLOYERS AND MANAGED CARE * Richard B. Lipton, MD ABSTRACT Migraine is a common disorder, affecting approximately 28 million men and women in the United
More informationUPDATE: Screening and Coverage for Diabetes and Prediabetes. Karin Gillespie, Changing Diabetes Policy, Novo Nordisk
UPDATE: Screening and Coverage for Diabetes and Prediabetes Karin Gillespie, Changing Diabetes Policy, Novo Nordisk 2 USPSTF Diabetes Screening Guideline New USPSTF Abnormal Blood Glucose and Type 2 Diabetes
More informationOncology Management at HAP. John Calabria, DO, Medical Director
Oncology Management at HAP John Calabria, DO, Medical Director Agenda Rising Cost of Health Care Ways of Managing Oncology Cost Pathways Update Where do we go from here? The Cost of Cancer Source: National
More informationBehavioral Health Hospital and Emergency Department Health Services Utilization
Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation
More informationMemorias Convención Internacional de Salud Pública. Cuba Salud La Habana 3-7 de diciembre de 2012 ISBN
Primary Health Care and the Management of the Ambulatory Care Sensitive Conditions of Hypertension and Diabetes in Jamaica Charlton McFarlane Ministry of Health and University of the West Indies and Natalie
More informationDental Care Remains the No. 1 Unmet Health Care Need for Children and Low-Income Adults
Oral Health and Access to Dental Care for Ohioans, 2007 Dental Care Remains the No. 1 Unmet Health Care Need for Children and Low-Income Adults Oral Health and Access to Dental Care for Ohioans, 2007
More informationWhat are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Ortega A, Dranitsaris G, Puodziunas A L Record Status This is a critical abstract of an economic evaluation
More informationThe financial impact of a cancer diagnosis
The financial impact of a cancer diagnosis Linda Sharp Aileen Timmons National Cancer Registry Ireland With the support of: Harry Comber, Director, National Cancer Registry (NCR) Noeleen Donnelly, Human
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationPatient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP)
Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP) May 2015 Summary Overview The American Society of Clinical Oncology (ASCO) has devoted considerable
More informationThe Value of Providing Collaborative Care Models For Treating Employees with Depression
The Value of Providing Collaborative Care Models For Treating Employees with Depression Summary Depression is one of the costliest health issues for employers because of its high prevalence and co-morbidity
More informationAccomplishments. Financial toxicities Church, spiritual, and faithbased
Accomplishments Thirteen years Record attendance Organization Disparities Screening and prevention Technology Research and Education Health Systems Financial toxicities Church, spiritual, and faithbased
More informationEconomics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P
Economics evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer Neymark N, Lianes P, Smit E F, van Meerbeeck J P Record Status This is a critical abstract of an economic
More informationOsteoporosis a bone disorder
Osteoporosis-Related Hip Fractures Cost $13 Billion to $18 Billion Yearly Eric Barefield (404) 880-6289 Osteoporosis a bone disorder associated with increased susceptibility to fracture of the hip, spine,
More informationKelly Fust 1 Xiaoyan Li. Richard Barron 2 Milton C. Weinstein. Gary H. Lyman 8
PharmacoEconomics (2017) 35:425 438 DOI 10.1007/s40273-016-0474-0 ORIGINAL RESEARCH ARTICLE Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia
More informationPalliative Care: Transforming the Care of Serious Illness
Palliative Care: Transforming the Care of Serious Illness Diane E. Meier, MD Director, Center to Advance Palliative Care diane.meier@mssm.edu www.capc.org www.getpalliativecare.org @dianeemeier No Disclosures
More informationNever has there been a more
ABattle We Can t Afford tolose The Burden of Overweight and Obesity in Texas: The Costs in Dollars and Lives Never has there been a more critical time to ensure a healthy future for our children. In the
More informationSetting The setting was the community. The economic study was conducted in Yokohama city, Japan.
Cost-benefit analysis of community based rehabilitation program using willingness to pay measured by the contingent valuation method Toida M, Takemura S Record Status This is a critical abstract of an
More informationMethodological issues in estimating the cost of epilepsy
Epilepsy Research 33 (1999) 39 55 Methodological issues in estimating the cost of epilepsy Charles E. Begley *, John F. Annegers, David R. Lairson, Thomas F. Reynolds The Uni ersity of Texas, Houston,
More informationPalliative Care and End of Life Care
Palliative Care and End of Life Care Relevant Data and References Victorian Population 1 Total Victorian Population as at June 2016 was 6.1 million (6,179,249) Victorian 60 plus population as at June 2016
More informationConnecticut Teachers' Retirement Board 2019 Medicare Supplement Plan Benefits -- Administered By Stirling Benefits. General information
Provider access Covered Benefits Deductible General information All providers who accept If covers a charge, then the TRB plan covers that charge The 2019 deductible is $185. The member pays the Part B
More informationTransition to Cancer Survivorship
Transition to Cancer Survivorship Zach Moore Dr. Barbara Norton FMSRE 2017- Project #1 Cancer Diagnosis Cancer Treatment Surgery Radiation Chemotherapy Cancer Survivor https://images.google.com/?gws_rd=ssl
More informationAbout the Highmark Foundation
About the Highmark Foundation The Highmark Foundation, created in 2000 as an affiliate of Highmark Inc., is a charitable organization and a private foundation that supports initiatives and programs aimed
More informationThe Impact of Tiered Co-Pays A Survey of Patients and Pharmacists
The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists Research Report Conducted by Harris Interactive September, 2003 This study was completed on behalf of and with support from the National
More informationTrends in Pneumonia and Influenza Morbidity and Mortality
Trends in Pneumonia and Influenza Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Health Education Division November 2015 Page intentionally left blank Introduction
More informationSMOKING, HEALTHCARE COST AND LOSS OF PRODUCTIVITY IN INDONESIA Created by: dr. DIAH EVASARI HUSNULKHOTIMAH, MPH
SMOKING, HEALTHCARE COST AND LOSS OF PRODUCTIVITY IN INDONESIA 2010 Created by: dr. DIAH EVASARI HUSNULKHOTIMAH, MPH 1. Introduction 1.1 Background of the Study 1.2 Research Question 1.3 Significance of
More informationFinancial toxicity and cancer patients. Yu-Ning Wong MD MSCE Fox Chase Cancer Center
Financial toxicity and cancer patients Yu-Ning Wong MD MSCE Fox Chase Cancer Center The Brains in the Outfit Federal Reserve Survey 47% of respondents say they either could not cover an emergency expense
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationBreast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity WORKING GROUP: This report will be written within the Cancer Control Working Group with oversight from the Second Malignant
More informationOverweight and Obesity Rates Among Upstate New York Adults
T H E F A C T S A B O U T Overweight and Obesity Rates Among Upstate New York Adults Upstate New York Obesity Rate: 27.5% Overweight Rate: 35.5% Increase in the combined overweight/ obesity rate from 2003
More informationPalliative Care for Older Adults in the United States
Palliative Care for Older Adults in the United States Nathan Goldstein, MD Associate Professor Hertzberg Palliative Care Institute Brookdale Department of Geriatrics and Palliative Medicine Icahn School
More informationVARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION
VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION
More informationADA 2007 Cost of Diabetes in the United States -
- Diabetes Educational Services Training Healthcare Professionals On State-of-the-Art Diabetes Care ADA 2007 Cost of Diabetes in the United States - Another Downloadable Article from the Diabetes Educational
More informationExamples of Nordic collaborations: benefits and challenges
Examples of Nordic collaborations: benefits and challenges There are numerous well working ongoing Nordic research collaborations, and some Nordic organizations that have a long track record of systematic
More informationSetting The setting was primary care. The economic study was conducted in the UK.
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the disability in strategies for care (DISC) study Sculpher M, Millson D, Meddis D, Poole L Record
More information2017 Community Oncology Alliance 1
2017 Community Oncology Alliance 1 The Value Of Community Oncology Lucio N. Gordan, MD Florida Cancer Specialists Director of Medical Informatics and Quality Disclosures American Oncology Network (AON)
More informationUsing claims data to investigate RT use at the end of life. B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center
Using claims data to investigate RT use at the end of life B. Ashleigh Guadagnolo, MD, MPH Associate Professor M.D. Anderson Cancer Center Background 25% of Medicare budget spent on the last year of life.
More informationEconomic effects of beta-blocker therapy in patients with heart failure Cowper P A, DeLong E R, Whellan D J, LaPointe N M, Califf R M
Economic effects of beta-blocker therapy in patients with heart failure Cowper P A, DeLong E R, Whellan D J, LaPointe N M, Califf R M Record Status This is a critical abstract of an economic evaluation
More informationDementia in Maine: Characteristics, Care and Cost Across Settings. 2013
Maine State Library Maine State Documents Aging And Disability Services Documents Health & Human Services 12-2013 Dementia in Maine: Characteristics, Care and Cost Across Settings. 2013 Maine Office of
More informationCHECK AGAINST DELIVERY:
Beijing launch of Preventing Chronic Disease: a vital investment Speech by Dr Catherine Le Galès-Camus, Assistant Director-General, World Health Organization, Non-communicable Diseases and Mental Health
More informationChapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration
s And Pilot Projects Chapter 18 Section 2 EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials 1.0 PURPOSE The purpose of this demonstration is to improve TRICARE-eligible
More informationEconomic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany Schadlich P K, Brecht J G
Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany Schadlich P K, Brecht J G Record Status This is a critical abstract of an economic evaluation
More informationStudy population Male and female patients with bipolar I disorders who had been hospitalised for acute mania.
A pharmacoeconomic model of divalproex vs lithium in the acute and prophylactic treatment of bipolar I disorder Keck P E, Nabulsi A A, Taylor J L, Henke C J, Chmiel J J, Stanton S P, Bennett J A Record
More informationARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY
ARE STROKE UNITS COST EFFECTIVE? EVIDENCE FROM A NEW ZEALAND STROKE INCIDENCE AND POPULATION-BASED STUDY Braden Te Ao, Ph.D. Centre for Health Services Research & Policy, University of Auckland, National
More informationCost-Utility Analysis (CUA) Explained
Pharmaceutical Management Agency Cost-Utility Analysis (CUA) Explained Cost-Utility Analysis (CUA) at PHARMAC Questions and Answers go to page 9 >> This document explains the process that PHARMAC generally
More informationwas proven to help people live longer1 BLINCYTO A guide for patients and caregivers
In a clinical trial for people with a certain kind of ALL whose cancer has returned or didn t respond to treatment 1 BLINCYTO was proven to help people live longer1 In a study of 405 adults with ALL, 271
More informationTotal financial cost to the U.S. Direct medical costs: Direct non-medical costs: Productivity losses: TOTAL: $16.2 billion $11.2 billion $8.
2 Annual Total Burden to the U.S. Economy of AMD, Cataract, Diabetic Retinopathy, Glaucoma, Refractive Errors, Visual Impairment and Blindness Total financial cost to the U.S. For the year 24, the total
More informationCost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY
Cost of Diabetes Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Christopher Stanley, MD, MBA American Diabetes Association Colorado Advocacy Chair Vice President of Population Health
More informationChapter 15 Section 1
Chapter 15 Section 1 Issue Date: November 6, 2007 Authority: 32 CFR 199.14(a)(3) and (a)(6)(ii) 1.0 APPLICABILITY This policy is mandatory for the reimbursement of services provided either by network or
More information2018 Candidate Guide. Leading in the fight to end Alzheimer's
2018 Candidate Guide Leading in the fight to end Alzheimer's Table of Contents Candidate Letter...2 2018 Alzheimer's Disease Facts and Figures...3 Federal Policies to Lead on Alzheimer's...4 State Policies
More information